CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an orally administered small-molecule p38 inhibitor targeting neuroinflammation and synaptic dysfunction. Neflamapimod is in clinical development for Dementia with Lewy Bodies (DLB), nonfluent variant primary progressive aphasia (nfvPPA), Rapid Eye Movement Sleep Behavior Disorder Associated Synucleinopathy (RAS), and ALS. There are no approved therapies for DLB in the US or EU.
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001437749-26-008259 | EDGAR | 90K words |
| 2025-03-17 | 2024-12-31 | 0001437749-25-007829 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001437749-24-010064 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0001437749-23-007795 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001437749-22-006737 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001437749-21-006236 | EDGAR | — |
| 2020-03-17 | 2019-12-31 | 0001437749-20-005469 | EDGAR | — |
| 2019-03-19 | 2018-12-31 | 0001437749-19-005256 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001437749-18-006050 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001437749-17-005713 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001437749-25-033879 | EDGAR | 25K words |
| 2025-08-08 | 2025-06-30 | 0001437749-25-025570 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001437749-25-015966 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001437749-24-034344 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001437749-24-025875 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001437749-24-016615 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031374 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001437749-23-022535 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014359 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027266 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001437749-22-020219 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001437749-22-012143 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001437749-26-009388 | EDGAR | 1K words |
| 2026-03-19 | 0001437749-26-009081 | EDGAR | — |
| 2026-03-17 | 0001437749-26-008611 | EDGAR | — |
| 2026-03-04 | 0001437749-26-006911 | EDGAR | — |
| 2026-02-18 | 0001437749-26-004555 | EDGAR | — |
| 2026-01-08 | 0001437749-26-000883 | EDGAR | — |
| 2025-12-05 | 0001437749-25-037025 | EDGAR | — |
| 2025-11-10 | 0001437749-25-034095 | EDGAR | — |
| 2025-11-04 | 0001437749-25-032869 | EDGAR | — |
| 2025-10-29 | 0001437749-25-032184 | EDGAR | — |
421 total filings indexed. 389 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001053691 |
| Ticker | CRVO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cervomed.com |
| Listed | 1996-06-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report